Medexus Pharmaceuticals (TSE:MDP) Stock Price Down 6.5% – Time to Sell?

Medexus Pharmaceuticals Inc. (TSE:MDPGet Free Report)’s stock price was down 6.5% during mid-day trading on Tuesday . The stock traded as low as C$4.39 and last traded at C$4.60. Approximately 231,189 shares were traded during mid-day trading, an increase of 52% from the average daily volume of 152,449 shares. The stock had previously closed at C$4.92.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MDP shares. Leede Financial upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, January 22nd. Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 17th. Stifel Nicolaus increased their target price on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research note on Tuesday, January 14th. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Finally, Raymond James upgraded Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 target price on the stock in a research note on Wednesday, January 8th. One analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Strong Buy” and a consensus target price of C$5.58.

View Our Latest Analysis on Medexus Pharmaceuticals

Medexus Pharmaceuticals Price Performance

The firm has a market cap of C$98.37 million, a price-to-earnings ratio of 80.20 and a beta of 1.96. The stock has a 50-day moving average of C$3.30 and a 200-day moving average of C$2.74.

Medexus Pharmaceuticals Company Profile

(Get Free Report)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

See Also

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.